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PCLINICAL RESEARCH Acute Myocardial Infarction
Plasma Concentrations of Myeloperoxidase
Predict Mortality After Myocardial Infarction
Tessa J. Mocatta, MSC,* Anna P. Pilbrow, PHD,† Vicky A. Cameron, PHD,†
Revathy Senthilmohan, PHD,† Chris M. Frampton, PHD,† A. Mark Richards, MD, PHD,†
Christine C. Winterbourn, PHD*
Christchurch, New Zealand
Objectives This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and
clinical outcome retrospectively in patients after acute myocardial infarction (MI).
Background Reactive oxidants are implicated in cardiovascular disease, and elevated plasma MPO is reported to predict ad-
verse outcome in acute coronary syndromes.
Methods Detailed demographic information, radionuclide ventriculography, neurohormone measurements, and clinical
history were obtained for 512 acute MI patients at hospital admission. Plasma levels of MPO and protein car-
bonyls were measured in patients and 156 heart-healthy control subjects. 3-Chlorotyrosine was measured in se-
lected patients. Patient mortality was followed for 5 years.
Results Plasma MPO and protein carbonyl concentrations were higher in MI patients 24 h to 96 h after admission than
in control subjects (medians: MPO 55 ng/ml vs. 39 ng/ml, and protein carbonyls 48 pmol/mg vs. 17 pmol/mg
protein, p  0.001 for each). Both markers were significantly correlated with each other and with cardiovascular
hormone levels. Chlorotyrosine was not elevated in patients with high MPO or carbonyl levels. Above-median
levels of MPO but not protein carbonyls were independently predictive of mortality (odds ratio 1.8, 95% confi-
dence interval 1.0 to 3.0, p  0.034). Patients with above-median MPO levels in combination with above-
median plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) or below-median left ventricular ejec-
tion fraction (LVEF) had significantly greater mortality compared with other patients.
Conclusions Myeloperoxidase and protein carbonyl levels are elevated in plasma after acute MI, apparently via
independent mechanisms. High MPO is a risk factor for long-term mortality and adds prognostic value to
LVEF and plasma NT-proBNP measurements. (J Am Coll Cardiol 2007;49:1993–2000) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.040c
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(eactive oxygen species are important contributors to car-
iovascular disease, including the events surrounding myo-
ardial infarction (MI) (1,2). They have been implicated in
umerous cardiovascular pathologies including endothelial
ysfunction, plaque rupture, ventricular remodeling, and
schemia/reperfusion injury during MI (3,4). Injury can be
he result of major insults such as lipid peroxidation or more
ubtle effects on signaling pathways (5,6). Reactive oxidants
rom the Departments of *Pathology and †Medicine, Christchurch School of
edicine and Health Sciences, University of Otago, Christchurch, New Zealand.
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007, accepted February 20, 2007.an modulate nitric oxide metabolism in endothelial cells
7,8), metalloprotease activation (9), and inactivation plas-
inogen activator inhibitor 1 (10).
See page 2001
There is increasing evidence that myeloperoxidase
MPO) contributes to cardiovascular disease (1,11,12). My-
loperoxidase is a neutrophil and monocyte enzyme that
mplifies the reactivity of hydrogen peroxide through gen-
ration of hypochlorous acid, free radicals, and reactive
itrogen species (13). Myeloperoxidase and products of
rotein oxidation by hypochlorous acid have been detected
n atheromatous lesions (14–17). High plasma MPO is
eported to be a risk factor for early adverse cardiac events in
atients with chest pain (18) or acute coronary syndromes
19) and to be associated with endothelial dysfunction
4,20). Elevations associated with heart failure (21,22)
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Myeloperoxidase After MI May 22, 2007:1993–2000might be useful for diagnosis in
the community (23). Whether
plasma MPO is a useful prog-
nostic marker of long-term sur-
vival in MI patients has not been
assessed.
We have compared plasma
MPO levels in acute MI patients
with matched control subjects
and related them to markers of
cardiac dysfunction (plasma amino-
terminal pro-brain natriuretic
peptide [NT-proBNP] and left ven-
tricular ejection fraction [LVEF])
and subsequent 5-year mortality.
We also investigated whether pro-
tein carbonyls, a widely used marker
of protein oxidation (24), are in-
creased in plasma after MI. To as-
sess whether the presence of MPO
in plasma resulted in hypochlorous
acid formation and whether this
could account for the carbonyl for-
mation, 3-chlorotyrosine, a specific
marker of hypochlorous acid react-
ng with tyrosine residues (25), was measured in a subgroup of
atients.
ethods
atients. Christchurch Hospital provides tertiary cardiac
ervices to a New Zealand population of approximately
00,000. Patients admitted with acute MI between Novem-
er 1994 and June 2001 were recruited to the Christchurch
ardioendocrine Post Myocardial Infarction study (26,27).
subgroup of 512 was randomly selected for this study.
nclusion criteria included age 80 years, absence of car-
iogenic shock, and survival for at least 24 h after MI. Acute
I was defined by the presence of typical cardiac ischemic
ymptoms, ischemic change on the electrocardiogram in 2
r more contiguous leads, and peak elevation of plasma
reatine kinase to at least twice normal (400 U/l). All
atients were troponin T positive (0.17 g /ml). Mortality
as followed for 5 years. Five patients were lost to follow-
p, although their data until withdrawal were included.
ate of death was confirmed by searching the National
ealth Index linked to the National Register of Deaths.
The mean age of patients was 61.7 years (range 32 to 80
ears), and 80% were male. Thirty-eight percent had dys-
ipidemia, 38% had documented hypertension, 13% had
ype 2 diabetes, 9% had heart failure, 37% had angina, and
8% had a previous history of MI. Current smokers repre-
ented 30%, and 37% had never smoked. The control
opulation consisted of 149 volunteers (70% male) ran-
omly selected from the Christchurch electoral roll, with a
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
IQR  interquartile range
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
MI  myocardial infarction
MPO  myeloperoxidase
NT-proANP  amino-
terminal pro-atrial
natriuretic peptide
NT-proBNP  amino-
terminal pro-brain natriuretic
peptide
PTCA  percutaneous
transluminal coronary
angioplastyean age of 64.7 years (range 42 to 83 years). The absence mf cardiovascular disease (heart failure, coronary artery
isease, or stroke) in control subjects was determined by
creening the National Health Information Database for
revious hospital admissions and by a questionnaire con-
rming that subjects had no cardiovascular symptoms. Of
he control subjects, 5% were current smokers and 51% had
ever smoked. The study was approved by the Canterbury
thics Committee (ethics reference: CTY/94/08/783 for
ost-MI Study, CTY/01/05/062 for Healthy Volunteer
tudy) and conformed to the principles outlined in the
eclaration of Helsinki. All participants gave written,
nformed consent.
V function. Left ventricular function, including LVEF
nd left ventricular end-systolic volume (LVESV), was
ssessed by radionuclide ventriculography within 24 h of
lood sampling. A General Electric 400AC gamma camera
nterfaced to a 3000I computer system (General Electric
edical Systems, Milwaukee, Wisconsin) was used, after
tandard in vivo technetium-99m red blood cell labeling.
iochemical and hormone assays. Blood samples were
aken 24 to 96 h after admission to hospital and again at 4
onths, in the morning, from an indwelling intravenous
annula placed at least 30 min before sampling and with the
atient resting quietly while semi-recumbent. Where pa-
ients received thrombolytic agents or underwent percuta-
eous transluminal coronary angioplasty (PTCA), samples
ere taken subsequent to treatment. Most patients received
eparin within a few hours of hospital admission. All blood
amples were collected in chilled ethylenediaminetetraacetic
cid (EDTA) tubes, placed immediately on ice, and centri-
uged within 20 min at 4°C. Plasma samples were stored at
80°C.
Protein carbonyls were analyzed on the EDTA plasma by
nzyme-linked immunosorbent assay (ELISA) after deriva-
ization with 2,4-dinitrophenylhydrazine (28) with Zentech
C kits (BioCell, Auckland, New Zealand). We have found
rotein carbonyls to be stable for a number of years of
torage at 80°C, and consistent with this, no relationship
as seen between date of collection of patient sample and
rotein carbonyl level (r  0.01, p  0.76).
Myeloperoxidase was measured by sandwich ELISA on
lasma diluted 1:10, with a monoclonal antibody (Abcam,
ambridge, United Kingdom) and a rabbit polyclonal
ntibody produced in-house. The detection range was 0.3 to
5 ng/ml, and the coefficient of variation was 13%. Control
nd patient samples were included on each plate. Results
btained with the in-house assay were linearly correlated
Pearson correlation coefficient 0.91, n  53) but were
.3-fold higher than those obtained with the Oxis MPO
LISA (Foster City, California). This difference is relevant
hen comparing studies. Median values of 120 and 198
mol/l (18 and 30 ng/ml) reported by Brennan et al. (18) for
ontrol subjects and chest pain patients were obtained with
he Oxis assay. The 10-fold higher median of 287 ng/ml
eported by Baldus et al. (22) for acute coronary syndromes,
easured with the Calbiochem ELISA, was obtained for
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May 22, 2007:1993–2000 Myeloperoxidase After MIerum, which we have found to give higher MPO values
han matched plasma samples.
Heparin administration to the patients was a possible
omplication, because it can mobilize MPO from the
ndothelium where it binds to negatively charged proteo-
lycans (20,29). Associations between heparin treatment
nd MPO were investigated retrospectively by reading
ospital notes of the patients with the highest MPO levels
n  20, mean MPO level  185 ng/ml) and a random
election of other patients (n  12, mean MPO level  44
g/ml). Approximately 60% of both groups were being
reated with heparin at the time of sampling. There was also
o association between MPO level and heparin treatment
median MPO, heparin treated: 145 [67 to 169], untreated:
49 [35 to 193] ng/ml, p  0.93). In a preliminary kinetic
tudy in 10 patients (M. Nallaratnam and T. Mocatta,
ersonal communication, 2007), MPO was found to in-
rease initially after heparin administration, in accordance
ith the findings of Baldus et al. (20), but was already
eclining at 2 h to 4 h and had returned to baseline within
4 h. The majority of the highest MPO patients had
ommenced heparin treatment at least 24 h before sam-
ling. In light of these findings, analysis of hospital notes for
dditional patients was deemed unnecessary.
3-Chlorotyrosine was measured in 4 groups of plasma
amples from patients selected on the basis of whether they
ad high or low protein carbonyl and MPO levels and from
random selection of control subjects. Total plasma pro-
eins were hydrolyzed with methane sulfonic acid with
henol added to minimize artifactual chlorination during
ample preparation, as described previously (30). Tyrosine
nd 3-chlorotyrosine were derivatized and analyzed by
sotope dilution gas chromatography/mass spectrometry
ith a Hewlett Packard 6890 gas chromatograph equipped
ith a ZB-50 capillary column interfaced to a Hewlett
ackard 5973 mass spectrometer (Hewlett Packard, Palo
lto, California). Artifactual tyrosine chlorination, mea-
ured with a second isotopically labeled tyrosine, accounted
or an average of 10 chlorotyrosine/million tyrosines and has
een subtracted. Interassay and intra-assay variation was
5% for values80 chlorotyrosine/million tyrosine, and 10
as the detection limit. Human serum albumin (Albumex,
ommonwealth Serum Laboratories, Melbourne, Austra-
ia) or control plasma (40 mg/ml protein in phosphate-
uffered saline pH 7.4) was treated with hypochlorous
cid solution (Sarah Lee, Auckland, New Zealand), by
apidly mixing equal volumes. After 30 min, excess
xidant was quenched with 1 mmol/l methionine and
liquots of the protein were assayed for protein carbonyls
nd chlorotyrosine.
Atrial natriuretic peptide (ANP) (31), amino-terminal
ro-atrial natriuretic peptide (NT-proANP) (31), brain
atriuretic peptide (BNP) (31), NT-proBNP (32), norepi-
ephrine (31), and adrenomedullin (33) were measured by
adioimmunoassay. Creatine kinase and troponin T were beasured with commercial ELISA kits (Boehringer Mann-
eim, Germany).
tatistical analysis. Levels of MPO and protein carbonyls
n MI patients were compared with levels in control subjects
ith analysis of variance (ANOVA). Within the MI patient
roup, relationships between MPO and protein carbonyl
evels and demographic data, treatment, ventricular func-
ion, and neurohormone levels were tested with chi-square,
NOVA, and Pearson’s correlation analyses. Levels of
PO, protein carbonyls, and neurohormones displayed
kewed distributions and were log transformed before anal-
sis. Results are expressed as medians and interquartile
anges (IQR). Bivariate relationships with measures of
ardiac function, including LVEF and LVESV, and levels
f circulating hormones were explored with Pearson’s cor-
elation in MI patients. Kaplan-Meier curves of patients
ith above/below-median MPO and protein carbonyls were
ompared with log-rank tests. Multivariate analysis was
erformed with a Cox proportional hazards model to
etermine independent associations between MPO and
stablished risk factors (age, gender, type 2 diabetes, LVEF,
lasma NT-proBNP, and plasma endothelin levels) and
urvival. Survival in patients from risk groups (above/below
edian MPO in combination with either above/below
edian LVEF or above/below median plasma NT-
roBNP) was compared with Kaplan-Meier curves and
og-rank tests. Statistical analyses were performed with
PSS version 11 (SPSS Inc., Chicago, Illinois). A p value
0.05 was considered significant.
esults
levated MPO and protein carbonyl concentrations in
I plasma. The characteristics of the acute MI patients
re given in Table 1. The MPO levels were elevated in
lasma obtained from these patients 24 to 96 h after
dmission (median and IQR: 55 [38 to 75] ng/ml, n 490)
ompared with control plasma (39 [29 to 49] ng/ml, n 
46, p  0.001), as shown in Figure 1A. Female patients
61 [42 to 83] ng/ml, n 97) had significantly higher MPO
evels than male patients (53 [37 to 73] ng/ml, n 393; p
.029).
The MI patients also had significantly elevated plasma
oncentrations of protein carbonyls 24 h to 96 h after
dmission (48 [23 to 73] pmol/mg protein, n  508)
ompared with control subjects (17 [0 to 50] pmol/mg, n 
56, p  0.001) (Fig. 1B). There was no significant
ifference between men and women (p 0.239). There was
weak positive correlation between concentrations of pro-
ein carbonyls and MPO (r  0.096, p  0.033).
For the patient samples collected in the 1 to 4 days after
ospital admission, levels of MPO or protein carbonyls were
o higher in those closer to admission (r  0.05, p  0.47
nd r  0.03, p  0.28, respectively, for the relationship
etween marker level and day of sampling, n  421).
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Myeloperoxidase After MI May 22, 2007:1993–2000rotein carbonyls also remained high at 4 months (59 [30 to
4] pmol/mg protein, n  242, p  0.047).
ssociations with heart function, severity indexes, and
reatment in MI patients. Neurohormonal levels and ven-
riculography indexes are established prognostic markers
fter MI (26,27). There were weak, statistically significant
ositive associations between plasma MPO levels and cir-
ulating levels of BNP, NT-proBNP, cyclic 3=,5=-guanosine
onophosphate (cGMP), adrenomedullin, and norepi-
ephrine, measured in patients at admission [r  0.14 to
.26, p  0.05]. There was no correlation with ANP or
T-proANP. Protein carbonyl levels were positively corre-
ated with ANP, NT-proANP, BNP, NT-proBNP, cGMP,
nd norepinephrine levels (r  0.13 to 0.16, p  0.05) but
ot adrenomedullin. Protein carbonyls were also correlated
ith ventriculography markers of cardiac dysfunction,
VESV (r  0.10, p  0.04) and LVEF (r  0.10, p 
.03).
There were no significant differences in either marker
haracteristics of MI Patient Population
Table 1 Characteristics of MI Patient Population
Demographic data
Number (M/F) 512 (410/102)
Age (yrs) 61.7  11.0
Age range (yrs) 32–80
Mortality over 5 yrs of follow-up 78 (15.3%)
Previous medical history
Type 2 diabetes 63 (12.7%)
Previous MI 85 (17.5%)
Drug treatments/interventions
Statin treatment before admission 13 (2.5%)
Thrombolytic treatment at admission 304 (62.6%)
PTCA 124 (24.8%)
ACE inhibitor treatment at discharge 210 (41.2%)
Beta-blocker treatment at discharge 363 (71.2%)
Cardiac function
ST-segment elevation 415 (81.1%)
Plasma creatine kinase (U/l) 1,658 (923–2,790)
Troponin T (g/l) 8.0 (3.5–15.6)
LVEF (%) 48  12
LVEDV (ml) 159  50
LVESV (ml) 86  43
Neurohormone markers
ANP (pmol/l) 28 (19–39)
NT-proANP (nmol/l) 1,230 (645–1,965)
BNP (pmol/l) 20 (13–29)
NT-proBNP (pmol/l) 110 (68–182)
cGMP (pmol/l) 7.0 (5.0–9.0)
Adrenomedullin (pmol/l) 9.3 (7.4–12.8)
Norepinephrine (pmol/l) 2,543 (1,840–3,521)
ge and ventriculography data are expressed as means and SD, plasma hormone and cardiac
arkers as medians and interquartile ranges.
ACE angiotensin-converting enzyme; ANP atrial natriuretic peptide; BNP brain natriuretic
eptide; cGMP cyclic guanosine monophosphate; LVEDV left ventricular end-diastolic volume;
VEF  left ventricular ejection fraction; LVESV  left ventricular end-systolic volume; MI 
yocardial infarction; NT-proANP  amino-terminal pro-atrial natriuretic peptide; NT-proBNP 
mino-terminal pro-brain natriuretic peptide; PTCA  percutaneous transluminal coronary
ngioplasty.etween patients who did and did not have PTCA (n 124s. 377, MPO p  0.61; protein carbonyls p  0.55) or
reatment with statins (n  13 vs. 471, MPO p  0.35;
rotein carbonyls p  0.54) at the time of admission.
lthough MPO levels did not differ between patients who
eceived thrombolytic therapy during admission and those
ho did not (n  304 vs. 182, p  0.79), protein carbonyl
evels were significantly lower in those receiving treatment
treated: 41 [19 to 68], untreated: 59 [39 to 84] pmol/mg,
 0.001). There were no significant differences in MPO
evels between patients treated or not treated with
ngiotensin-converting enzyme inhibitors (n  210 vs. 300,
 0.44) or beta-blockers at discharge (n  363 vs. 147, p
0.35). Protein carbonyl levels did not differ in patients
reated with angiotensin-converting enzyme inhibitors (p 
Figure 1 Plasma Concentrations of Myeloperoxidase
and Protein Carbonyls in Patients After MI
(A) Myeloperoxidase and (B) protein carbonyls, with patient data in red and
control data in blue. Boxes show medians and interquartile ranges with
whiskers and symbols representing the 10th/90th and 5th/95th percentiles,
respectively. Both markers were significantly higher for patients than control
subjects (p  0.001). MI  myocardial infarction.
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May 22, 2007:1993–2000 Myeloperoxidase After MI.21) but were lower in patients prescribed beta-blockers
treated: 44 [20 to 70], untreated: 59 [35 to 86] pmol/mg,
 0.001).
elationships to MI patient survival. Of the MI patients,
8 died during the 5-year follow-up. Above-median levels
f MPO were significantly associated with a nearly 2-fold
ncrease in mortality (above-median MPO mortality: 21%,
elow-median MPO mortality: 10%, p  0.001) (Fig. 2A).
here was no significant association between levels of
rotein carbonyls and survival (p  0.31) (Fig. 3B).
Cox proportional hazards analysis indicated that older
ge, pre-existing type 2 diabetes, below-median LVEF, and
bove-median levels of plasma NT-proBNP and plasma
PO were significantly predictive of mortality in this MI
Figure 2 Kaplan-Meier Cumulative Survival Curves for
MI Patients Show a Difference for MPO But Not PCs
(A) Comparison of patients with (red) above-median and (blue) below-median
myeloperoxidase (MPO) concentrations (median 55 ng/ml; p  0.001); and
(B) patients with above- and below-median protein carbonyls (median 48
pmol/mg; p  0.31), over a 5-year follow-up. MI  myocardial infarction; PC 
protein carbonyl.latient cohort. Above median MPO contributed to mortality
ndependently of the other factors (p  0.03, risk ratio  1.8,
5% confidence interval 1.1 to 3.1) (Table 2). The effects of
PO and both LVEF and plasma NT-proBNP were
dditive in predicting post-MI mortality (Fig. 3). Patients
ith above-median MPO in combination with a below-
edian LVEF (Fig. 3A) had significantly worse survival
han all the other groups, with 5-fold higher mortality than
hose with low MPO and high LVEF. Similarly, patients
ith above-median levels of MPO and plasma NT-proBNP
Fig. 3B) had significantly worse survival than other groups
nd 6-fold greater mortality than those with below-median
Figure 3 MPO Provides Further Discrimination in
Survival When Combined With LVEF or NT-proBNP
Kaplan-Meier cumulative survival curves for myocardial infarction patients with
above- and below-median myeloperoxidase (MPO) over a 5-year follow-up in
combination with (A) above- and below-median left ventricular ejection fraction
(LVEF) (p  0.0001) and (B) above- and below-median plasma amino-terminal
pro-brain natriuretic peptide (NT-proBNP) levels (p  0.0001). Differences in
survival between patient groups are indicated, except for between groups A
and B where there was no significant difference. Medians: MPO  55 ng/ml;
protein carbonyls  48 pmol/mg; LVEF  49%; NT-proBNP  110 pmol/l.evels of both markers.
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Myeloperoxidase After MI May 22, 2007:1993–2000elationships to 3-chlorotyrosine levels. To examine
hether high MPO levels in MI plasma were active in
roducing hypochlorous acid and whether hypochlorous
cid could be the source of the elevated protein carbonyls,
hlorotyrosine was measured in total plasma protein from
elected patients with upper or lower quartile levels of
rotein carbonyls, MPO, or both. In all the groups, chlo-
otyrosine was close to the level of detection and no higher
han in control plasma (Table 3). There were no significant
ifferences between groups that varied by 5-fold in mean
PO concentration or by 20-fold in protein carbonyls. If
ypochlorous acid were the source of protein carbonyls in
he patient samples, relative amounts of carbonyls and
hlorotyrosine should be similar to those in purified human
lbumin or control plasma that had been treated with
eagent hypochlorous acid. However, for both albumin and
lasma, amounts of hypochlorous acid that gave protein
arbonyls in the range seen for patient plasma generated 100
imes more chlorotyrosine than measured in the patient
amples (Fig. 4). These results imply that any hypochlorous
cid generated by MPO in the plasma is insufficient to be
etected by this sensitive technique and unlikely to be the
ource of protein carbonyls.
ox Proportional Hazardsnalysis f Factors Pre ictive of Death
Table 2 Cox Proportional HazardsAnalysis of Factors Predictive of Death
Variable Risk Ratio 95% CI p Value
LVEF (above- vs. below-median) 2.54 1.43–4.52 0.002
Type 2 diabetes 2.24 1.25–4.03 0.007
Plasma NT-proBNP (above- vs. below-median) 1.83 1.03–3.26 0.039
Plasma MPO (above- vs. below-median) 1.81 1.07–3.05 0.026
Gender (male vs. female) 1.30 0.71–2.38 0.395
Age (yrs) 1.05 1.02–1.08 0.001
Plasma protein carbonyls (above- vs. below-
median)
0.85 0.52–1.39 0.513
ignificant (p  0.05) p values indicated in bold type. Medians: LVEF  49%, NT-proBNP  110
mol/l, MPO  55 ng/ml, protein carbonyls  48 pmol/mg.
CI  confidence interval; MPO  myeloperoxidase; other abbreviations as in Table 1.
-Chlorotyrosine Levels in Total Plasma Proteinrom MI Patients With High or Low MPO andtein Carbo yl
Table 3
3-Chlorotyrosine Levels in Total Plasma Protein
From MI Patients With High or Low MPO and
Protein Carbonyls
Group
MPO
(ng/ml)
Protein Carbonyls
(pmol/mg) Cl-Tyr/Million Tyr
1: high MPO/high PC 126 39 113 21 8 6
2: high MPO/low PC 126 73 15 10 12 10
3: low MPO/high PC 36 9 93 21 12 9
4: low MPO/low PC 26 8 4 5 19 21
Control subjects 52 7 26 28 15 5
roup 1, protein carbonyls (PC) and myeloperoxidase (MPO) levels in the upper quartile; group 2,
pper quartile MPO and lower quartile carbonyls; group 3, lower quartile MPO and higher quartile
arbonyls; group 4, both markers in the lower quartile. Each group contained 12 to 14 samples
xcept control subjects (n  5); means  SD are shown. There were no significant differences ini
hlorotyrosine (Cl-Tyr) levels between any of the groups.
MI  myocardial infarction; Tyr  tyrosine.iscussion
e found that plasma concentrations of both MPO and
rotein carbonyls measured after hospital admission for
cute MI patients were significantly higher than in a
atched control population. Levels of MPO were indepen-
ently predictive of 5-year survival and might provide
dditional prognostic information if used in combination
ith the established markers, LVEF and NT-proBNP.
PO and adverse clinical outcomes. Our observed 1.4-
old higher median MPO concentration in MI patients than
n control subjects is comparable to the difference reported
or patients with chest pain (18), 23% of whom had MI at
valuation. Our results are consistent with the MPO con-
ent of neutrophils being low in MI patients (34) and the
ource of the MPO being neutrophil degranulation. The
arkers did not appear acutely elevated in samples collected
losest to the onset of symptoms. This agrees with low
eutrophil content of MPO persisting for 72 h (34) and
mplies that elevation is not a transient event. Although
elease of MPO into plasma from the endothelium owing to
eparin (20,29) was a potential confounder, we found no
vidence that the extent or timing of heparin administration
as responsible for the high MPO levels. However, the
mpact of heparin administration on MPO levels in heart
atient needs further, more direct investigation.
A striking finding in previous studies of patients with
hest pain (18) and acute coronary syndromes (19) was that
lasma MPO concentration at enrolment was a strong
redictor of adverse outcomes (MI or death) that occurred
ithin hours or a few days, especially in patients with low
roponin T or C-reactive protein. Those studies suggested
hat MPO measurements might have clinical utility for
Figure 4 Relationships Between
Protein Carbonyls and 3-Chlorotyrosine
The oxidative markers were generated in human serum albumin (solid trian-
gles) and normal plasma (open triangles) by treatment with hypochlorous acid
(HOCl) and compared with those for myocardial infarction plasmas (circles).
CI-Tyr  chlorotyrosine; PMI  post-myocardial infarction; Tyr  tyrosine.dentifying risk of imminent cardiac events in a mixed
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May 22, 2007:1993–2000 Myeloperoxidase After MIohort of acute cardiac and non-cardiac patients where MI
s not yet confirmed. Our study focused on a different
atient population, with a confirmed MI diagnosis who had
lready survived 24 h to 96 h after MI. This study design
ould have excluded many of the early events. In this group,
lasma MPO levels were independently prognostic of mor-
ality over a 5-year follow-up. Furthermore, MPO in
ombination with LVEF or NT-proBNP provided more
iscrimination than any 1 measure. Mortality was 6-fold
igher for patients with both MPO and NT-proBNP above
he group median than for those with both below the
edian, and significant differences were also seen between
bove- and below-median MPO and LVEF groups. These
ovel findings suggest that measurement of MPO after
I could give long-term prognostic information and
mprove risk stratification, particularly when used in
ombination with the established markers, LVEF and
lasma NT-proBNP. As analyzed by Ng et al. (23) for
creening for heart failure, inclusion of MPO might also
rovide a cost benefit.
Although MPO levels were positively correlated with a
ange of neurohormone markers of severity, these relation-
hips were weak and the adverse association between MPO
nd survival was independent of LVEF or NT-proBNP.
his suggests that MPO levels contribute to mortality
ndependently of the degree of cardiac remodelling or
eurohormonal activation after MI.
Acute treatment with statins has been reported to down-
egulate MPO expression in macrophages (35). We saw no
nfluence on plasma levels of MPO by prior treatment with
tatins, but the treated numbers are small and this needs
ubstantiating with a larger study. The MPO levels were
lso not affected by PTCA or thrombolytic drugs.
xidized proteins, MPO, and acute MI. Protein carbon-
ls are elevated in heart failure (21) but have not been
easured previously in coronary heart disease. The higher
lasma concentrations in MI patients than control subjects
rovide evidence of oxidative stress and protein oxidation in
hese patients. These findings complement other reports of
aised levels of lipid peroxidation products such as
-isoprostane (36,37) and another putative oxidative
arker, advanced oxidation protein products (38). Tran-
ient increases in isoprostanes have also been detected in
oronary sinus after angioplasty and reperfusion (37,39).
igh protein carbonyls were not associated with increased
ortality. However, they were weakly correlated with cir-
ulating levels of prognostic hormone markers and with
ndexes of poor cardiac function.
Although plasma MPO was elevated in MI patients, we
ound no corresponding increase in chlorotyrosine. There-
ore, it is highly unlikely that MPO activity is the source of
rotein carbonyls in MI patient plasma. Other oxidants
ormed during ischemia and reperfusion or by activation of
ascular nicotinamide adenine dinucleotide (phosphate)
xidases (2,5,6) are possible alternative sources. The con-
inued elevation in protein carbonyls at 4 months suggestshat levels might be chronically raised in association with
he underlying vascular disease.
Proteins from atherosclerotic lesions contain more chlo-
otyrosine than control aorta (16), and high-density li-
oprotein has been shown to be preferentially chlorinated
17,40). Our observations imply that any chlorinated pro-
eins released from the lesion are insufficient to elevate total
lasma levels. The low chlorotyrosine levels in plasma with
igh MPO suggests that circulating MPO might have low
hlorinating ability. Possible explanations include the en-
yme being inactive or limited by the availability of hydro-
en peroxide.
onclusions
lasma MPO and protein carbonyl levels were higher in
atients after MI than in control subjects. High levels of
PO were independently prognostic of mortality over a
-year follow-up and, in combination with low LVEF or
igh plasma NT-proBNP, were associated with an even
reater mortality than any of these risk factors alone.
yeloperoxidase shows promise as a prognostic marker of
ong-term mortality in patients with a confirmed MI diag-
osis, particularly when used in combination with the other
stablished markers.
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